Clinical Trials Logo

Clinical Trial Summary

This is a pilot study of combination low dose rate brachytherapy (LDR) added to standard of care (SOC) immunotherapy in stage III and IV melanoma, stage IV renal call cancer, and stage IV urothelial cancer.


Clinical Trial Description

The purpose of this study is to evaluate the effect of combining LDR with immune checkpoint inhibition in stage III and IV melanoma, stage IV renal call cancer, and stage IV urothelial cancer. This involves the addition of a treatment called brachytherapy to SOC immunotherapy. Brachytherapy is a form of radiation therapy where radioactive pellets are placed within a tumor to temporarily irradiate the tumor at a low level. This is the first time that this combination (immunotherapy and brachytherapy) has been used in humans. The objectives of this study are to evaluate the effect of combining LDR with immunotherapy, determine safety and feasibility, generate a toxicity profile, evaluate response, and overall survival. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04620603
Study type Interventional
Source Case Comprehensive Cancer Center
Contact Jay Ciezki, MD
Phone 1-866-223-8100
Email TaussigResearch@ccf.org
Status Recruiting
Phase Phase 1/Phase 2
Start date May 27, 2021
Completion date March 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT01392729 - An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA) N/A
Completed NCT00520403 - A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer. Phase 2
Completed NCT00694096 - Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response Phase 1
Completed NCT00216801 - Relationship of Ochratoxin A to Upper Urologic Cancers N/A
Completed NCT00172003 - Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Phase 4
Completed NCT02493751 - A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100) Phase 1
Recruiting NCT01967407 - IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy. Phase 1/Phase 2
Completed NCT00509704 - Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma N/A
Terminated NCT05061537 - Study of PF-07263689 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT04535921 - Fear of Cancer Recurrence in Genitourinary Cancer
Completed NCT01829841 - A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer Phase 2
Completed NCT01122615 - Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) Phase 1
Completed NCT00979329 - Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST N/A
Active, not recruiting NCT02429440 - Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides Phase 1/Phase 2
Recruiting NCT06362369 - A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Phase 1/Phase 2
Active, not recruiting NCT02684006 - A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) Phase 3
Completed NCT02375776 - Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention N/A
Completed NCT01598597 - An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite) N/A
Completed NCT00465179 - Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer Phase 2
Completed NCT01158534 - Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery Phase 2